ASXL1 and acute myeloid leukemia: In particular, we identified significant upregulation of VANGL2 (BOS log2FC = 3.80, AML-ASXL1 log2FC = 4.24) (Fig. 2C) and GRIK5 (BOS log2FC = 3.83, AML-ASXL1 log2FC = 4.67) (Fig. 2D) in both BOS and AML-ASXL1 and significant downregulation of GREM2 in both conditions (BOS log2FC=-2.48, AML-ASXL1 log2FC=-1.67) (Fig. 2E; Table 2).